文献速递头颈外科

头颈癌随机临床试验的中止与未发表率

Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2020-01-01

该研究评估头颈癌随机临床试验(RCT)的中止与未发表率。在ClinicalTrials.gov检索并分析130项RCT,发现29.2%被中止,完成试验中40.2%在完成3年以上仍未发表;非企业资助试验的发表率显著高于企业资助试验。

要点

  • 头颈癌RCT中29.2%被中止,最常见原因是委员会建议。
  • 完成试验中40.2%在完成3年以上仍未发表。
  • 非企业资助试验的发表概率显著高于企业资助试验。

核心结论

  • 头颈癌RCT中29.2%被中止,完成试验中40.2%未发表,提示需要加强RCT指导。

研究设计与样本

  • 于2019年3月18日通过ClinicalTrials.gov高级检索功能获取截至该日期注册的已完成和中止的头颈癌RCT,分析中止原因和发表状态。

主要发现

  • 共纳入130项RCT,其中92项(70.8%)完成,38项(29.2%)中止。
  • 中止最常见原因为委员会建议。
  • 130项试验中67项(51.5%)发表于同行评议期刊,63项(48.5%)未发表。
  • 92项完成试验中55项(59.8%)发表,37项(40.2%)在完成3年以上仍未发表。
  • 非企业资助(私人、非营利或NIH)试验比企业资助RCT更可能发表(未调整OR=4.3,95%CI 1.3-14.0;调整OR=4.1,95%CI 1.2-14.3)。

临床怎么用

  • 临床医生和研究者应关注头颈癌RCT的中止和未发表问题,警惕研究证据的缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials (RCTs) play an important role in clinical decision-making, and discontinuation or nonpublication of these trials are causes of great concern. The extent of discontinued or unpublished RCTs about head and neck cancer remains unclear. OBJECTIVE: To assess the rate of discontinuation or nonpublication of RCTs involving patients with head and neck cancer. This objective was measured by observing 3 domains: discontinuation of trial, nonpublication of trial data, and feasibility of contacting trial investigators of aforementioned trials. EVIDENCE REVIEW: For this study, the sample was derived using the ClinicalTrials.gov advanced search feature on March 18, 2019, to locate completed and discontinued RCTs pertaining to head and neck cancer registered before this date. Trials were analyzed to identify reasons for trial discontinuation and publication status of each trial. If publication status or reason for trial discontinuation was not allocated through the systematic search of ClinicalTrials.gov, the corresponding author was emailed to determine publication status. FINDINGS: After exclusions, 130 RCTs were included. Of these trials, 92 (70.8%) were completed and 38 (29.2%) were discontinued for various reasons. The most common reason for discontinuation of trials was committee recommendations. Of the 130 analyzed trials, 67 (51.5%) were published in a peer-reviewed journal and 63 (48.5%) were unpublished trials. Of the 92 completed trials, 55 (59.8%) were published and 37 (40.2%) remained unpublished 3 or more years after trial completion. Trials funded by other sources (private, nonprofit, or the National Institutes of Health) were more likely to reach publication than industry-funded RCTs (unadjusted odds ratio, 4.3 [95% CI, 1.3-14.0]; adjusted odds ratio, 4.1 [95% CI, 1.2-14.3]). CONCLUSIONS AND RELEVANCE: Of RCTs in head and neck cancer, 29.2% were discontinued and 40.2% completed trials never reached publication. The findings suggest that needs exist for RCT guidance of head and neck cancer. The reporting of reasons for trial discontinuation appears to be lacking, and trial publication rates were low. This study is relevant to many physicians and researchers because it identifies potential sources of decreased research productivity and ethics.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Johnson AL, Fladie I, Anderson JM, et al. Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 31876933. doi:10.1001/jamaoto.2019.3967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。